BOSTON--(BUSINESS WIRE)--Nov 4, 2026--
Dunkin’ is bringing the excitement of Marvel Studios’ “Avengers: Doomsday,” in theaters December 18, beyond the big screen with a new campaign starring Channing Tatum as Gambit.
Click to Gallery
Dunkin’ and Marvel Studios' “Avengers: Doomsday” bring guests the Avenging Donut and Avenging MUNCHKINS® Donut Hole Treats, as well as the Doomsday Donut and Doomsday MUNCHKINS® Donut Hole Treats, now available at participating Dunkin’ restaurants nationwide.
Dunkin’ and Marvel Studios’ “Avengers: Doomsday” bring guests a limited-time lineup of character-inspired beverages, now available at participating Dunkin’ restaurants nationwide.
Fans can bring home the collectible Doctor Doom 25-count MUNCHKINS® Tin, available at participating Dunkin' restaurants, while supplies last.
Dunkin's limited-edition Marvel Studios' “Avengers: Doomsday” collectibles are now available at participating restaurants nationwide, featuring Avengers: Doomsday-themed tumblers, color-changing mugs, and character and glove cup sleeves.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104532694/en/
Even Super Heroes run on Dunkin’. Channing Tatum reprises his role as Gambit alongside H.E.R.B.I.E., the Fantastic Four's robotic companion, in Dunkin's new “MUNCHKIN Incursion” spot celebrating its new collaboration with Marvel Studios' “Avengers: Doomsday.”
The experience extends beyond the campaign with immersive restaurant transformations, a character-inspired menu and limited-edition collectibles.
Channing Tatum Returns as Gambit
Before facing an unprecedented threat, even Gambit needs a Dunkin’ run. To celebrate the nationwide launch, Dunkin’ is debuting “ MUNCHKIN Incursion,” a new commercial featuring Channing Tatum reprising his role as Gambit alongside H.E.R.B.I.E., the Fantastic Four’s beloved robotic companion.
As the pair prepare for what lies ahead, Gambit reaches for an Iced Captain’ccino while H.E.R.B.I.E. arrives with Doomsday and Avenging MUNCHKINS® Donut Hole Treats. But when worlds begin to collide, their routine doughnut break becomes anything but ordinary.
“Marvel fans have a deep connection to these characters and stories, and collaborating with Marvel Studios ‘Avengers: Doomsday’ has allowed us to bring that excitement into the everyday Dunkin’ experience,” said Jill Nelson, chief marketing officer at Dunkin’. “Whether guests are discovering the campaign, visiting one of our transformed restaurants or exploring the menu and collectibles, there’s a fun way for every fan to join the action.”
Four Cities. Four Worlds. One Epic Takeover.
Beginning Nov. 17, four Dunkin’ restaurants will transform into immersive destinations, each bringing a distinct corner of the Marvel Cinematic Universe to life:
The transformed locations will remain in place through early December, giving fans the opportunity to experience the worlds of Marvel’s heroes and villains during their next Dunkin’ visit.
“Marvel Studios’ ‘Avengers: Doomsday’ brings heroes from across three universes together as they face an unthinkable threat,” said Holly Frank, Vice President of Global Partnerships, Marvel Studios. “Dunkin’ plays on these high stakes in a fun spot with Gambit and Herbie and experiential activations that invite fans to engage with the film through unexpected moments both inside and beyond its restaurants.”
The Avengers: Doomsday Menu and Collectibles Have Arrived
The Dunkin’ “Avengers: Doomsday” lineup is available now at participating restaurants nationwide, featuring beverages, treats and limited-edition collectibles inspired by the film’s heroes and villains. Fans can choose their allegiance with menu items and merch inspired by some of Marvel’s most iconic characters:
From character-inspired beverages and collectibles to immersive restaurant experiences, Dunkin’ is giving Marvel fans new ways to fuel up for Doomsday before it hits theaters this December.
About Dunkin’
Dunkin’, founded in 1950, is the largest coffee and donuts brand in the United States, with more than 14,200 restaurants in nearly 40 global markets. Dunkin’ is part of the Inspire Brands family of restaurants. For more information, visit DunkinDonuts.com and InspireBrands.com.
About Marvel Studios’ “Avengers: Doomsday”
In Marvel Studios’ “Avengers: Doomsday,” beloved heroes from three distinct universes will be set on a deadly collision course and face an existential threat unlike anything they’ve ever encountered. The film, which is directed by Anthony and Joe Russo and written by Stephen McFeely and Michael Waldon, is produced by Kevin Feige, Louis D’Esposito and Jonathan Schwartz, stars Robert Downey Jr., Chris Evans, Chris Hemsworth, Pedro Pascal, Paul Rudd, Anthony Mackie, Florence Pugh, Vanessa Kirby, Ebon Moss-Bachrach, Wyatt Russell, Channing Tatum, Simu Liu, Ian McKellen, Hayley Atwell, Tom Hiddleston, James Marsden, Patrick Stewart, Joseph Quinn, Sebastian Stan, David Harbour, Letitia Wright, Lewis Pullman, Kelsey Grammer, Kathryn Newton, Danny Ramirez, Winston Duke, Alan Cumming, Hannah John-Kamen, Rebecca Romijn, Alex Livinalli, Mabel Cadena, with Tenoch Huerta Mejia. “Avengers: Doomsday” releases in theaters December 18, 2026.
Dunkin’ and Marvel Studios' “Avengers: Doomsday” bring guests the Avenging Donut and Avenging MUNCHKINS® Donut Hole Treats, as well as the Doomsday Donut and Doomsday MUNCHKINS® Donut Hole Treats, now available at participating Dunkin’ restaurants nationwide.
Dunkin’ and Marvel Studios’ “Avengers: Doomsday” bring guests a limited-time lineup of character-inspired beverages, now available at participating Dunkin’ restaurants nationwide.
Fans can bring home the collectible Doctor Doom 25-count MUNCHKINS® Tin, available at participating Dunkin' restaurants, while supplies last.
Dunkin's limited-edition Marvel Studios' “Avengers: Doomsday” collectibles are now available at participating restaurants nationwide, featuring Avengers: Doomsday-themed tumblers, color-changing mugs, and character and glove cup sleeves.
CORALVILLE, Iowa & FARGO, N.D.--(BUSINESS WIRE)--Nov 4, 2026--
Danaher companies Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a premier manufacturing partner for DNA, RNA, and protein, are jointly launching new research-grade mRNA solutions designed to simplify base and prime editing workflows. The launch brings IDT’s gene editing expertise and Aldevron’s mRNA manufacturing together within Danaher’s connected ecosystem to address researchers’ increasingly specialized editing needs. Building on the companies’ recently launched wild type and Spy Fi™ high-fidelity S.p. Cas9 mRNA portfolio, the expanded offering gives researchers more mRNA options for applications requiring precise, programmable changes to genomic DNA without double-strand breaks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104375435/en/
Meeting the shift to precision editing
As mRNA delivery and next-generation editing approaches advance, developers face increasingly specialized challenges: improving prime editing efficiency, narrowing pegRNA candidates for testing, and identifying base editors suited to their targets. Addressing these challenges takes complementary expertise across multiple workflow steps. Within Danaher’s connected science ecosystem, IDT and Aldevron bring CRISPR engineering, guide RNA design, and analysis expertise together with mRNA manufacturing to develop solutions around those needs. The resulting portfolio connects options for designing, screening, and optimizing base and prime editing workflows, helping researchers reduce complexity and maintain greater continuity as programs progress.
“The challenge is not simply to make more editing tools available—it is to bring the right capabilities together around the problems researchers need to solve,” said Christopher Vakulskas, senior director, applied science and molecular design at Integrated DNA Technologies. “Together with Aldevron, we’re addressing the realities of increasingly precise gene editing workflows by combining PE Ultra mRNA, optimized Alt-R pegRNAs, and enhanced design support that narrows testing to a practical set of candidates. Bringing these solutions together connects scientific expertise with practical workflow needs, helping researchers reduce complexity and move their programs forward with greater confidence.”
Tackling efficiency and targeting hurdles
Base editing enables a single, targeted nucleotide change, while prime editing supports precise substitutions, insertions, and deletions. Both do so without creating a double-strand break in the target DNA, an important consideration for researchers developing therapeutic applications. Prime editing, however, often struggles to reach efficient editing rates across targets and cell types. To address this, IDT and Aldevron developed PE Ultra mRNAs, which feature an engineered prime editor, and Alt‑R™ pegRNAs that contain a proprietary chemical modification pattern designed to enhance editing performance.
For base editing, researchers can face a different challenge such as protospacer‑adjacent motif (PAM) restrictions and variable editor activity, which can limit the number of targetable sites and make it difficult to identify the optimal editor for a given application. For greater flexibility, the companies now offer six stocked ABE8e-based mRNA variants spanning different PAM compatibilities and fidelity profiles, plus a screening kit for evaluating all six editors in parallel.
IDT has also released Alt-R CRISPR-Cas9 sgRNA XT to maximize editing performance across both base editing and Cas9-mediated workflows using mRNA. Together with the new IDT bioinformatics tool for pegRNA design, these solutions give researchers connected options for designing, screening, and optimizing precision-editing workflows.
Building a more connected gene editing portfolio
The launch builds on IDT and Aldevron’s September 2026 introduction of stocked research-grade S.p. Cas9 mRNA in wild type and Spy Fi™ high-fidelity formats. That initial offering provided mRNA-based options for gene editing workflows, which are particularly well-suited for in vivo applications, and established a path to scaled CGMP-manufactured versions for streamlined progression of therapeutic programs.
The new stocked base and prime editing mRNA products are orderable at scales of 20 ug to 1 mg, with larger scales available at Aldevron via custom order. For product details and data, visit www.IDTDNA.com/BasePrimeEditing.
Disclaimer: Integrated DNA Technologies (IDT) offers both Research Use Only (RUO) and In Vitro Diagnostic (IVD) products; Aldevron provides Research Grade (RG) and Current Good Manufacturing Practice (CGMP) products. RUO and RG products are intended for research use only and are not for use in diagnostic or therapeutic procedures. IVD and CGMP products are intended for diagnostic or clinical applications as specified in product documentation. References to clinical, diagnostic, or therapeutic impact pertain only to products with appropriate regulatory clearance. Purchasers are responsible for ensuring appropriate use and compliance with applicable regulations. For further information about product classifications and intended uses, please contact our regulatory affairs team or refer to product documentation.
About IDT
Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.
For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, YouTube, Instagram and Bluesky.
About Aldevron
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us.
About Danaher
Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many of their most complex scientific challenges by accelerating discovery, development and delivery of life-changing therapies. Powered by the Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and Innovation at the Speed of Life. Explore more at www.danaher.com.
Integrated DNA Technologies (IDT) and Aldevron are jointly launching new research-grade mRNA solutions for base and prime editing. New offerings include PE Ultra mRNA, chemically modified Alt-R pegRNAs, pegRNA design support, six stocked ABE8e base editor mRNAs, and a parallel screening kit. These connected options help researchers design, screen, and optimize precision-editing workflows, reduce complexity, and identify solutions suited to their targets
